Dare Bioscience, Inc.
corporate_fare Company Profile
Dare Bioscience, Inc. (NASDAQ:DARE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for DARE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for DARE spans DEF 14A, 8-K, PRE 14A, S-1.
Recent high-impact activity:
- Dare Bioscience Sets Nov 10 Vote on 45% Warrant Dilution
- Dare Bioscience Hit With Second Nasdaq Delisting Notice — Now Below $1 Minimum Bid Price
- Dare Bioscience Seeks Stockholder Approval for Warrant Exercise That Could Dilute Shares by 45%
- Dare Bioscience Registers Resale of 8.9M Warrant Shares From $6M Offering
- Dare Bioscience Details $6M Offering: Warrants, Fees, and Lock-Ups
Financial Snapshot
Short Interest & Short Volume
6.07 days to coverFINRA reported short interest of 986,092 shares in DARE as of the October 30, 2026 settlement, a 13.8% decrease from the prior period — about 6.1 days to cover at its recent average daily volume. On November 20, 2026, 23.1% of DARE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for DARE, detected from its recent SEC filings · based on capital-structure filings through 2026-08-17.
Registered Direct Offering Priced · Concurrent Private Placement Warrants
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →